)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Avadel Pharmaceuticals
Avadel Pharmaceuticals (AVDL) investor relations material
Avadel Pharmaceuticals has been acquired
Avadel Pharmaceuticals Proxy Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy Filing summary19 Dec, 2025
Executive summary
Alkermes and Avadel are progressing toward closing an acquisition, aiming to integrate their organizations and leverage complementary strengths for greater impact in treating hypersomnolence disorders, with integration planning underway for 2026.
A virtual town hall is scheduled for late January 2026 to address employee questions and introduce Alkermes senior leaders involved in the integration.
Forward-looking statements highlight anticipated benefits of the acquisition, while acknowledging risks such as regulatory approvals, competing offers, and potential delays.
Voting matters and shareholder proposals
Shareholders are to vote on the acquisition at a Scheme Meeting and an Extraordinary General Meeting (EGM), with the record date set as November 25, 2025.
Voting decisions should be based on the Definitive Proxy Statement, which includes the Scheme Document outlining terms and conditions of the acquisition.
Board of directors and corporate governance
Directors of both Avadel and Alkermes accept responsibility for the accuracy of the information provided in the communication, in compliance with Irish Takeover Rules.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Avadel Pharmaceuticals
- LUMRYZ growth, new pipeline assets, and strong financials drive optimism for future milestones.AVDL
Morgan Stanley 23rd Annual Global Healthcare Conference - LUMRYZ's growth accelerates with strong uptake, market expansion, and break-even achieved.AVDLJefferies London Healthcare Conference 2024
- LUMRYZ sales drove record Q3 revenue, expanded FDA approval, and sharply reduced losses.AVDLQ3 2024
- LUMRYZ sees robust growth, legal wins, and expanding access, with pipeline and market focus ahead.AVDL2024 Wells Fargo Healthcare Conference
- LUMRYZ's once-nightly dosing drives rapid patient growth, market expansion, and near-term profitability.AVDLMorgan Stanley 22nd Annual Global Healthcare Conference
- Rapid patient growth and strong financials support a $1B+ market opportunity.AVDLH.C. Wainwright 26th Annual Global Investment Conference 2024
- Q2 revenue hit $41.5M, net loss narrowed, and FDA review for pediatric use is pending.AVDLQ2 2024
- LUMRYZ targets a broad narcolepsy market with strong data, focused access, and growth in new and switch patients.AVDLGoldman Sachs 45th Annual Global Healthcare Conference
- 2025 guidance targets $240–$260M revenue, expanded patient reach, and improved persistency.AVDLQ4 2024 Guidance
- 2025 revenue guidance of $240–$260M reflects strong growth, new approvals, and robust IP protection.AVDLQ4 2024
Avadel Pharmaceuticals
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Avadel Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing innovative treatments for chronic conditions, particularly in the central nervous system (CNS) field. The company's flagship product, LUMRYZ™, is an extended-release formulation of sodium oxybate used to treat cataplexy and excessive daytime sleepiness in adults with narcolepsy. The company is headquartered in Dublin, Ireland, and its shares are listed on the NASDAQ.